Category Archives: R&D

Pharma in Argentina: An Interview with Juan Pablo Bagó

2014 marked the 80th anniversary of Laboratorios Bagó, a market leader in Argentina and also  Latin America, with products in  in 47 countries. In this interview with Pharmaboardroom.com, Juan Pablo Bagó, general director of pharma in Argentina for the Bagó group, discusses the state of R&D in Argentina, and explains why his group is planning for a 75 percent of turnover […]
Also posted in Emerging Markets, Global, Strategy | Tagged , , , , | Leave a comment

Randomized Trials Key to Determining Effectiveness of Ebola Therapies and Vaccines

US researchers and regulators continue to support the use of randomized clinical trials to test potential treatments and vaccines to combat the Ebola virus, despite objections that this approach is unethical and unfair to vulnerable populations. Anthony Fauci, director of the National Institute of Allergy & Infectious Diseases (NIAID), articulated the case for “gold-standard” randomized […]
Also posted in healthcare, Regulatory | Tagged , , , , | Leave a comment

Risking It All? Risk-Based Monitoring at Cancer Research UK

“Only those who risk going too far can possibly find out how far they can go,” said T.S. Elliot. Cancer Research UK (CRUK) followed this advice when it decided to have its Center for Drug Development (CDD) adopt a risk-based monitoring (RBM) approach across its entire portfolio of clinical trials. This decision has revealed how risk-adjusted approaches […]
Also posted in Strategy | Tagged , , , , | Leave a comment

Tufts Figures on Drug Development Spark Debate

By Agnes Shanley, Pharmaceutical Technology. The Tufts University Center for the Study of Drug Development (CSDD) released its latest research on the costs and timeframes required for launching a new drug. Although the study acknowledges that it still takes about 10 years to launch a new brand-name pharmaceutical, this year, the costs required were estimated at $2.6 […]
Also posted in Strategy | Tagged , , | 1 Comment

Tufts Pegs Drug Development Cost at $2.6 billion – MSF Cries Foul

A cool $2.6 billion is the going rate to develop and gain market approval for a drug, according to the recent study by the Tufts Center for the Study of Drug Development (CSDD).
Posted in R&D | Tagged , , | Leave a comment
  • Categories

  • Meta